Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation.
Liang, Y., Shao, S., Li, X.Y., Zhao, Z.X., Liu, N., Liu, Z.M., Shen, F.J., Zhang, H., Hou, J.W., Zhang, X.F., Jin, Y.Q., Du, L.F., Li, X., Zhang, J., Su, J.G., Li, Q.M.(2024) Science 385: 1484-1491
- PubMed: 39325881 
- DOI: https://doi.org/10.1126/science.adp2362
- Primary Citation of Related Structures:  
8YE3 - PubMed Abstract: 
The respiratory syncytial virus (RSV) fusion (F) glycoprotein is highly immunogenic in its prefusion (pre-F) conformation. However, the protein is unstable, and its conformation must be stabilized for it to function effectively as an immunogen in vaccines. We present a mutagenesis strategy to arrest the RSV F protein in its pre-F state by blocking localized changes in protein structure that accompany large-scale conformational rearrangements. We generated a series of mutants and screened them in vitro to assess their potential for forming a stable pre-F. In animals, the immunogenicity of a representative mutant F protein, with a conformation confirmed by cryo-electron microscopy, elicited levels of neutralizing antibodies and protection against RSV-induced lung damage that were comparable to those of DS-Cav1, a pre-F used in a licensed vaccine.
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China.
Organizational Affiliation: